Disclaimers:
Submission of a safety report does not constitute an admission that medical personnel, user facility, importer, distributor, manufacturer or product caused or contributed to the event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Data provided in the Quarterly Data Extract (QDE) or a FAERS FOIA report are a snapshot of FAERS at a given time. There are several reasons that a case captured in this snapshot can be marked as inactive and not show up in subsequent reports. Manufacturers are allowed to electronically delete reports they submitted if they have a valid reason for deletion. FDA may merge cases that are found to describe a single event, marking one of the duplicate reports as inactive. The data marked as inactive are not lost but may not be available under the original case number.

Processed Case Id's for Images:
14554565 14554619 14554625 14554687

Failed Case Id's for Images:

Total Failed Cases: 0
Age/Gender: 53 years/female

Substances: 1. Acetaminophen/Diphenhydramine, 2. Mitragyna speciosa korthals (botanic name), Ethanol

Relative Contribution to Fatality: Undoubtedly responsible

Chronicity of Exposure: Chronic

Route of Exposure: Ingestion

Reason for Exposure: Intentional-Intentional - Misuse

Pre-Hospital Arrest: No

Abstract:
Scenario/Substances: A 53-year-old woman was admitted with 24 hours of confusion after taking multiple doses of acetaminophen/diphenhydramine for several days with ethanol and possibly kratom. The last dose of apap was about 36 hours prior to admission.

Past Medical History: Not Provided.

Medications: Unknown

Physical Exam: Drowsy, confused, BP 89/45, HR 80.

Laboratory Data: Initial ALT 460, AST 1791, INR 5.2 and peaked at 7.5. APAP and aspirin negative. Creatinine 3.4 mg/dL. Bicarbonate 15. Ammonia peaked at 566 micrograms/dL, total bilirubin peaked at 18 mg/dL. Lactate rose to 25 mg/dL.

Clinical Course: She developed fulminant hepatic failure and encephalopathy despite intravenous N-acetylcysteine. Her course was complicated by renal failure and anuria, treated with continuous renal replacement therapy, sepsis treated with antibiotics, coagulopathy that was treated with vitamin K, fresh
frozen plasma and cryoprecipitate, and hypotension that was treated with IV fluids and 3 vasopressors. She was intubated, given oxygen, placed on the ventilator and given sedation medications on the 4th hospital day for respiratory failure. She failed to respond to these therapies and died on the 8th hospital day.

**Tissue/Substance Concentrations:** Not available.

**Autopsy Findings:** Not done.
Age/Gender: 22 years/male

Substances: 1 Mitragyna speciosa korthals (botanic name) (kratom)

Relative Contribution to Fatality: Probably responsible
Chronicity of Exposure: Unknown
Route of Exposure: Ingestion
Reason for Exposure: Unknown-Unknown reason
Pre-Hospital Arrest: Yes

Abstract:
Scenario/Substances: 22 year old male using Kratom was found unresponsive by his mother in the morning.

Past Medical History: None.

Medications: Unknown.

Physical Exam: Temperature 29 oC on arrival.

Laboratory Data: Serum APAP, ethanol and salicylate: not detected. UDS was positive for benzodiazepine. INR 2.7; Lactate 4.6. Creatinine 1.18; AST 6846, ALT 8295; CPK 5684.

Clinical Course: Patient received prehospital ACLS, intubation and ventilation. He was hypothermic on arrival and rewarmed. He had no brainstem reflexes throughout his hospitalization. Elevated CPK and transaminases were felt to be consistent with rhabdomyolysis, suggesting a long down time. These values decreased to AST 4088 and ALT 4496; CPK rose to 7761. Patient was treated with supportive care and IV fluids. An EEG showed no CNS activity. After 2 days a family meeting was held and he was allowed to expire.
**Tissue/Substance Concentrations:** Not available.

**Autopsy Findings:** Not performed.
Age/Gender: 38 years/female

Substances: 1) Mitragyna speciosa korthals (botanic name) Diphenhydramine
2) 

Relative Contribution to Fatality: Probably responsible

Chronicity of Exposure: Acute

Route of Exposure: Ingestion

Reason for Exposure: Intentional-Intentional - Suspected suicide

Pre-Hospital Arrest: No

Abstract:

Scenario/Substances: 38-year-old female presented to ED via EMS after an intentional ingestion of unknown amount of diphenhydramine and Kratom, mitragyna substance of abuse.

Past Medical History: Not Provided.

Medications: Unknown

Physical Exam: Unresponsive and intubated.

Laboratory Data: ECG: QRS 160

Clinical Course: In the ED, she had a seizure, not controlled with benzodiazepines and subsequently went into cardiac arrest. She was intubated, CPR/ACLS initiated, with intermittent ROSC, but with bradycardia in 30s bpm and hypotension. In the effort, phystostigmine and Lipid Emulsion Rescue Therapy was given without improvement. Resuscitative efforts were conducted for over an hour, and was ultimately unsuccessful.

Tissue/Substance Concentrations: Not available.
**Autopsy Findings:** Not available.
Age/Gender: 29 years/female

Substances: Mitragyna speciosa korthals (botanic name), Benzodiazepines

Relative Contribution to Fatality: Unknown

Chronicity of Exposure: Unknown

Route of Exposure: Ingestion

Reason for Exposure: Unknown-Unknown reason

Pre-Hospital Arrest: Yes

Abstract:

Scenario/Substances: 29-year-old female found down and unresponsive by her spouse. Upon EMS arrival, patient was apneic and pulseless. Patient was intubated, CPR/ACLS initiated, and transported to ED. Per family, patient had history of taking Kratom, a botanical called Mitragyna, substance of abuse.

Past Medical History: Bipolar Disorder

Medications: Unknown

Physical Exam: Unresponsive and intubated. BP 110/70, HR 71, O2 sat 100% on ventilator, T 93F.

Laboratory Data: ABG-pH 7.16 / pCO2 381 / pO2 55 / HCO3 10.0 BMP: Na 137 / K 4.4 / Cl 100 / CO2 18 / BUN 19 / Cr 1.5 / Glu 270 / AG 25 LACTATE: 14.6 mMol/L CK: 713 U/L Serum APAP 2.8 Ethanol and salicylate were not detected. UDS was positive for benzodiazepine. CXR: Aspiration ECG: HR 80, QRS 108, QTc 406

Clinical Course: In the ED, patient had ROSC, however coded 4 additional times. Post-resuscitation, she was placed on ventilator management, had a metabolic acidosis, a CXR showing an aspiration pneumonia, was
hemodynamically unstable, requiring 3 vasopressors for support, and started on the amiodarone. Patient remained unresponsive and hemodynamically unstable. Based on the prognosis, the family opted for institution of comfort measures and she died on Day #3.

**Tissue/Substance Concentrations:** Not available.

**Autopsy Findings:** Not available.
Disclaimers:

Submission of a safety report does not constitute an admission that medical personnel, user facility, importer, distributor, manufacturer or product caused or contributed to the event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Data provided in the Quarterly Data Extract (QDE) or a FAERS FOIA report are a snapshot of FAERS at a given time. There are several reasons that a case captured in this snapshot can be marked as inactive and not show up in subsequent reports. Manufacturers are allowed to electronically delete reports they submitted if they have a valid reason for deletion. FDA may merge cases that are found to describe a single event, marking one of the duplicate reports as inactive. The data marked as inactive are not lost but may not be available under the original case number.

The FOIA case report information may include both Electronic Submissions (Esubs) and Report Images (Non-Esubs). Case ID(s) will be displayed under separate cover pages for the different submission types.

Cover page Case ID(s) with an asterisk (**) indicate an invalid status and are not captured in the body of the report.

Esub Case ID(s) Submitted:

14254346  14449343

Run by:  STEPPERH
Date - Time:  23-FEB-2018 11:49 AM
Total number of cases (Esub):  2
Total number of inactive cases:  0
Case Information:

Case ID: 14254346

Case Type: EXPEDITED (15-DAY)  eSub: Y  HP:  Country: USA  Event Date:  Outcomes: DE, OT, Application Type: NDA

FDA Rcvd Date: 05-Dec-2017  Mfr Rcvd Date: 30-Nov-2017  Mfr Control #: US-GLAXOSMITHKLINE-US2017GSK183857  Application #: 018644

Patient Information:

Age: 27 YR  Sex: Male  Weight:

Suspect Products:

<table>
<thead>
<tr>
<th>#</th>
<th>Product Name</th>
<th>Compounded Drug?</th>
<th>Dose/Frequency</th>
<th>Route</th>
<th>Dosage Text</th>
<th>Indications(s)</th>
<th>Start Date</th>
<th>End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bupropion</td>
<td></td>
<td>Unknown</td>
<td>UNK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Dextromethorphan</td>
<td></td>
<td>Unknown</td>
<td>UNK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Ethanol</td>
<td></td>
<td>Unknown</td>
<td>UNK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>MITRAGYNA SPECIOSA (MITRAGYNINE)</td>
<td></td>
<td>Unknown</td>
<td>UNK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#</th>
<th>Product Name</th>
<th>Interval 1st Dose to Event</th>
<th>DeC</th>
<th>ReC</th>
<th>Lot#</th>
<th>Exp Date</th>
<th>NDC #</th>
<th>MFR/Labeler</th>
<th>OTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bupropion</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td>GLAXOSMITHKLINE</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Dextromethorphan</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td>GLAXOSMITHKLINE</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Ethanol</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td>GLAXOSMITHKLINE</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>MITRAGYNA SPECIOSA (MITRAGYNINE)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td>GLAXOSMITHKLINE</td>
<td></td>
</tr>
</tbody>
</table>

Event Information:

Preferred Term (MedDRA® Version: 20.1)  ReC

Cardio-respiratory arrest  NA
Death  NA
Drug abuse  NA
Case ID: 14254346

Event/Problem Narrative:
This case was reported in a literature article and described the occurrence of unknown cause of death in a 27-year-old male patient who received bupropion hydrochloride (Bupropion) tablet for an unknown indication. (Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report. Clinical Toxicology 2017; : .) 

Co-suspect products included dextromethorphan hydrobromide (Dextromethorphan) unknown for an unknown indication, ethanol unknown for an unknown indication and mitragyna speciosa for an unknown indication.

On an unknown date, the patient started Bupropion (unknown) at an unknown dose and frequency, Dextromethorphan (unknown) at an unknown dose and frequency, ethanol (unknown) at an unknown dose and frequency and mitragyna speciosa (unknown) at an unknown dose and frequency.

On an unknown date, an unknown time after starting Bupropion, Dextromethorphan and ethanol, the patient experienced unknown cause of death (serious criteria death and GSK medically significant), drug abuse (serious criteria death and GSK medically significant) and cardiopulmonary arrest (serious criteria GSK medically significant). On an unknown date, the outcome of the unknown cause of death and drug abuse were fatal and the outcome of the cardiopulmonary arrest was unknown. The reported cause of death was unknown cause of death and drug abuse. An autopsy was performed.

The reporter considered the unknown cause of death, drug abuse and cardiopulmonary arrest to be related to Bupropion, Dextromethorphan and ethanol.

Additional Information:

This case corresponds to case number 358 in the literature article.

Suspect drug U-47700 was deemed by the reporter to be most responsible for the patient's death.

Following exposure to the suspect drugs for an unspecified time (described as acute), the patient died due to death NOS and drug abuse. Autopsy was performed and details reviewed- u-47700 was measured at 4.6 mg/kg, Dextromethorphan 12 mg/kg, Diphenhydramine 3.7 mg/kg in liver at autopsy. Ethanol 70 mg/dL in brain at autopsy. No information was provided about the patient's medical history or any concurrent medication. No dates were provided.

The reporter considered the suspect drugs were undoubtedly responsible for the patient's death, commenting "In the opinion of the Clinical Review Team the clinical case evidence established beyond a reasonable doubt that the (suspect drug) actually caused the death. No further information was available."
## Case ID: 14254346

### Relevant Medical History:

<table>
<thead>
<tr>
<th>Disease/Surgical Procedure</th>
<th>Medical History Product(s)</th>
<th>Start Date</th>
<th>End Date</th>
<th>Continuing?</th>
<th>Indications</th>
<th>Events</th>
</tr>
</thead>
</table>

### Relevant Laboratory Data:

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Result</th>
<th>Unit</th>
<th>Normal Low Range</th>
<th>Normal High Range</th>
<th>Info Avail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug level</td>
<td>12</td>
<td>mg/kg</td>
<td></td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Drug level</td>
<td>4.6</td>
<td>mg/kg</td>
<td></td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Drug level</td>
<td>70</td>
<td>mg/dL</td>
<td></td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Drug level</td>
<td>3.7</td>
<td>mg/kg</td>
<td></td>
<td></td>
<td>N</td>
</tr>
</tbody>
</table>

### Concomitant Products:

<table>
<thead>
<tr>
<th>#</th>
<th>Product Name</th>
<th>Dose/Frequency</th>
<th>Route</th>
<th>Dosage Text</th>
<th>Indications(s)</th>
<th>Start Date</th>
<th>End Date</th>
<th>Interval 1st Dose to Event</th>
</tr>
</thead>
</table>

### Reporter Source:

- **Study Report?**: No
- **Sender Organization**: GLAXOSMITHKLINE
- **503B Compounding Outsourcing Facility?**:

### Literature Text:

Case ID: 14449343

Case Information:
- Case Type: EXPEDITED (15-DAY)
- eSub: Y
- HP: Country: USA
- Event Date: Outcomes: DE,
- Application Type: ANDA

FDA Rcvd Date: 27-Jan-2018
Mfr Rcvd Date: 02-Jan-2018
Mfr Control #: US-ENDO PHARMACEUTICALS INC-2018-013940

FDA Rcvd Date: 27-Jan-2018
Mfr Rcvd Date: 02-Jan-2018
Mfr Control #: US-ENDO PHARMACEUTICALS INC-2018-013940
Application #: 077284

Patient Information:
- Age: 27 YR
- Sex: Male
- Weight:

Suspect Products:

<table>
<thead>
<tr>
<th>#</th>
<th>Product Name</th>
<th>Compounded Drug ?</th>
<th>Dose/ Frequency</th>
<th>Route</th>
<th>Dosage Text</th>
<th>Indications(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bupropion HCl XL</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>UNK UNK, Unknown</td>
<td>Product used for unknown indication</td>
</tr>
<tr>
<td>2</td>
<td>DEXTROMETHORPHAN</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>UNK UNK, Unknown</td>
<td>Product used for unknown indication</td>
</tr>
<tr>
<td>3</td>
<td>DIPHENHYDRAMINE</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>UNK UNK, Unknown</td>
<td>Product used for unknown indication</td>
</tr>
<tr>
<td>4</td>
<td>ETHANOL</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>UNK UNK, Unknown</td>
<td>Product used for unknown indication</td>
</tr>
<tr>
<td>5</td>
<td>Mitragyna speciosa korthals</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>UNK UNK, Unknown</td>
<td>Product used for unknown indication</td>
</tr>
<tr>
<td>6</td>
<td>U-47700</td>
<td></td>
<td></td>
<td>Unknown</td>
<td>UNK UNK, Unknown</td>
<td>Product used for unknown indication</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#</th>
<th>Product Name</th>
<th>Interval 1st Dose to Event</th>
<th>DeC</th>
<th>ReC</th>
<th>Lot#</th>
<th>Exp Date</th>
<th>NDC #</th>
<th>MFR/Labeler</th>
<th>OTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bupropion HCl XL</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td>PAR</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>DEXTROMETHORPHAN</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>DIPHENHYDRAMINE</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>ETHANOL</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Mitragyna speciosa korthals</td>
<td></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>U-47700</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Case ID: 14449343**

**Event Information:**

<table>
<thead>
<tr>
<th>Preferred Term (MedDRA® Version: 20.1)</th>
<th>ReC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardio-respiratory arrest</td>
<td>NA</td>
</tr>
<tr>
<td>Drug abuse</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Event/Problem Narrative:**

This is case 3 out of 49 cases for bupropion hydrochloride found in the 2016 American Association of Poison Control Centers (AAPCC) toxicology report received on 02-Jan-2018.

This domestic literature report involved a human poison exposure report on a 27-year-old male (Case 358 from the 2016 AAPCC toxicology report Table 21. Listing of fatal non pharmaceutical and pharmaceutical exposures) who was exposed to bupropion (strength, dose and manufacturer unspecified) in combination with unknown dosage of U-47700, dextromethorphan, diphenhydramine, ethanol and mitragyna speciosa korthals. The reason for exposure was intentional abuse. The patient had an acute exposure and experienced a pre-hospital cardiac and/or respiratory arrest and subsequently died in 2016 (exact date unknown).

Autopsy records were reviewed. The analytes reported for the case were U-47700, dextromethorphan, diphenhydramine and ethanol. At the time of autopsy, U-47700 concentration in liver was 4.6mg/kg. At the time of autopsy, dextromethorphan concentration in liver was 12mg/kg. At the time of autopsy, diphenhydramine concentration in liver was 3.7mg/kg. At the time of autopsy, ethanol concentration in brain was 70mg/dL.

Author's Comments: Bupropion was ranked 6 out of 6 suspect substances and was ranked sixth as the cause rank by the Case Review Team. In the opinion of the Case Review Team the Clinical Case Evidence establishes beyond a reasonable doubt that the SUBSTANCES actually caused the death.


On Oct 01, 2013, FDA granted Par Pharmaceutical Inc., a waiver of the requirement under 21 CFR 314.80, to submit post marketing 15 day "Alert Reports", resulting from the Annual Report of the American Association of Poison Control Centers (AAPCC) Toxic Exposure Surveillance System, within 30 days of initial receipt of information instead of 15 days. This waiver is in effect for ANDA 077284 until written notification of discontinuation.

**Relevant Medical History:**

<table>
<thead>
<tr>
<th>Disease/Surgical Procedure</th>
<th>Start Date</th>
<th>End Date</th>
<th>Continuing?</th>
</tr>
</thead>
</table>

Print Time: 23-FEB-2018 11:49 AM
Case ID: 14449343

<table>
<thead>
<tr>
<th>Medical History Product(s)</th>
<th>Start Date</th>
<th>End Date</th>
<th>Indications</th>
<th>Events</th>
</tr>
</thead>
</table>

Relevant Laboratory Data:

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Result</th>
<th>Unit</th>
<th>Normal Low Range</th>
<th>Normal High Range</th>
<th>Info Avail</th>
</tr>
</thead>
</table>

Concomitant Products:

<table>
<thead>
<tr>
<th>#</th>
<th>Product Name</th>
<th>Dose/ Frequency</th>
<th>Route</th>
<th>Dosage Text</th>
<th>Indications(s)</th>
<th>Start Date</th>
<th>End Date</th>
<th>Interval</th>
<th>1st Dose to Event</th>
</tr>
</thead>
</table>

Reporter Source:

<table>
<thead>
<tr>
<th>Study Report?</th>
<th>Sender Organization</th>
<th>Outsourcing Facility?</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>ENDO</td>
<td>503B Compounding</td>
</tr>
</tbody>
</table>

Literature Text:

Disclaimers:
Submission of a safety report does not constitute an admission that medical personnel, user facility, importer, distributor, manufacturer or product caused or contributed to the event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Data provided in the Quarterly Data Extract (QDE) or a FAERS FOIA report are a snapshot of FAERS at a given time. There are several reasons that a case captured in this snapshot can be marked as inactive and not show up in subsequent reports. Manufacturers are allowed to electronically delete reports they submitted if they have a valid reason for deletion. FDA may merge cases that are found to describe a single event, marking one of the duplicate reports as inactive. The data marked as inactive are not lost but may not be available under the original case number.

Processed Case Id's for Images:
14190720  14291010  14291011  14356493

Failed Case Id's for Images:

Total Failed Cases: 0
ED ATCH
The FDA Safety Information and Adverse Event Reporting Program

A. PATIENT INFORMATION

1. Patient Identifier
   (8) (8)

2. Age
   - Year(s) Month(s)
   - Week(s) Day(s)
   or Date of Birth (e.g., 08 Feb 1925)

3. Sex
   - Female
   - Male

4. Weight
   - lb
   - kg

5.a. Ethnicity (Check single best answer)
   - Hispanic/Latino
   - Not Hispanic/Latino

5.b. Race (Check all that apply)
   - Asian
   - American Indian or Alaskan Native
   - Black or African American
   - White
   - Native Hawaiian or Other Pacific Islander

B. ADVERSE EVENT, PRODUCT PROBLEM

1. Check all that apply
   - Adverse Event
   - Product Problem (e.g., defects/malfunctions)
   - Product Use Error
   - Problem with Different Manufacturer of Same Medicine

2. Outcome Attributed to Adverse Event (Check all that apply)
   - Death: Include date (dd-mm-yyyy):
   - Life-threatening
   - Disability or Permanent Damage
   - Hospitalization – Initial or prolonged
   - Congenital Anomaly/Birth Defects
   - Other Serious (Important Medical Events)
   - Required intervention to Prevent Permanent Impairment/Damage (Devices)

3. Date of Event (dd-mm-yyyy)
4. Date of this Report (dd-mm-yyyy)

5. Describe Event, Problem or Product Use Error
   This report refers to

6. Relevant Tests/Laboratory Data, Including Dates

7. Other Relevant History, Including Preexisting Medical Conditions (e.g., allergies, pregnancy, smoking and alcohol use, liver/kidney problems, etc.)

C. PRODUCT AVAILABILITY

2. Product Available for Evaluation? (Do not send product to FDA)
   - Yes
   - No
   - Returned to Manufacturer on (dd-mm-yyyy)

D. SUSPECT PRODUCTS

1. Name, Manufacturer/Compounder, Strength (from product label)
   #1 – Name and Strength
   KTRAM
   #1 – NDC # or Unique ID
   #2 – Name and Strength
   #2 – Manufacturer/Compounder

2. Name and Strength
   #2 – NDC # or Unique ID
   #2 – Lot #

E. SUSPECT MEDICAL DEVICE

1. Brand Name
2. Common Device Name
3. Model #
4. Lot #
5. Operator of Device
   - Medical Professional
   - Lay User/Trader
   - Other

F. OTHER (CONCOMITANT) MEDICAL PRODUCTS

Product names and therapy dates (Exclude treatment of event)

G. REPORTER (See confidentiality section on back)

1. Name and Address
   Last Name:
   First Name:
   Address:
   City:
   State/Province/Region:
   Country:
   ZIP/Postal Code:
   Phone #:
   Email:

2. Health Professional? Yes No
3. Occupation

4. Also Reported to
   - Manufacturer/Compounder
   - User Facility
   - Distributor/Importer

5. If you do NOT want your identity disclosed to the manufacturer, please mark this box: 

Note: For date prompts of “dd-mm-yyyy” please use 2-digit day, 3-letter month abbreviation, and 4-digit year, for example, 01-Jul-2015.

FORM FDA 3500 (10/15) Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event.
B.5. Describe Event or Problem (continued)
Please see the attached articles for further details.

B.6. Relevant Tests/Laboratory Data, Including Dates (continued)

B.7. Other Relevant History, Including Preexisting Medical Conditions (e.g., allergies, pregnancy, smoking and alcohol use, hepatic renal dysfunction, etc.) (continued)

F. Concomitant Medical Products and Therapy Dates (Exclude treatment of event) (continued)
### A. PATIENT INFORMATION

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Year(s)</td>
<td>Month(s)</td>
<td>Female</td>
</tr>
<tr>
<td></td>
<td>Week(s)</td>
<td>Days(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Date of Birth (e.g., 08 Feb 1925)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.a. Ethnicity (Check single best answer)
- [ ] Hispanic/Latino
- [ ] Asian
- [ ] American Indian or Alaskan Native
- [ ] Black or African American
- [ ] White
- [ ] Not Hispanic/Latino
- [ ] Native Hawaiian or Other Pacific Islander

5.b. Race (Check all that apply)
- [ ] Asian
- [ ] American Indian or Alaskan Native
- [ ] Black or African American
- [ ] White
- [ ] Not Hispanic/Latino
- [ ] Native Hawaiian or Other Pacific Islander

### B. ADVERSE EVENT, PRODUCT PROBLEM

1. Check all that apply
- [ ] Adverse Event
- [ ] Product Problem (e.g., defects/malfunctions)
- [ ] Product Use Error
- [ ] Problem with Different Manufacturer of Same Medicine

2. Outcome Attributed to Adverse Event (Check all that apply)
- [X] Death (Include date (dd-mm-yyyy))
- [ ] Life-threatening
- [ ] Disability or Permanent Damage
- [ ] Hospitalization – Initial or prolonged
- [ ] Congenital Anomaly/Birth Defects
- [ ] Other Serious (Important Medical Events)
- [ ] Required intervention to Prevent Permanent Impairment/Damage (Devices)

### E. SUSPECT MEDICAL DEVICE

1. Brand Name
2. Common Device Name
3. Manufacturer Name, City and State
4. Model #
5. Lot #
6. Operator of Device
- [ ] Health Professional
- [ ] Lay User/Patient
- [ ] Other
7. Catalog #
8. Expiration Date (dd-mm-yyyy)
9. Unique Identifier (UDI) #
10. If Implanted, Give Date (dd-mm-yyyy)
11. If Explanted, Give Date (dd-mm-yyyy)

### F. OTHER (CONCOMITANT) MEDICAL PRODUCTS

Product names and therapy dates (Exclude treatment of event)

### G. REPORTER (See confidentiality section on back)

1. Name and Address
2. Health Professional?
- [ ] Yes
- [ ] No
3. Occupation
- [ ] Healthcare Professional
4. Also Reported to:
- [ ] Manufacturer/Componder
- [ ] User Facility
- [ ] Distributor/Importer

Note: For dates prompts of “dd-mm-yyyy” please use 2-digit day, 3-letter month abbreviation, and 4-digit year, for example, 01-Jul-2015.
B.5. Describe Event or Problem (continued)
DDI received a call from reporter (b)(6). CDER/OC/Incident team followed up with the reporter, who was too distraught to provide details regarding her (b)(6) death, other than to state that the coroner said death was due to Kratom. CDER/OC/Incident team also contacted the reporter's (b)(6) (b)(6), at (b)(6) and via telephone, who promised to complete a MedWatch and provide coroner and toxicology reports. Those reports have not been received.

B.6. Relevant Tests/Laboratory Data, Including Dates (continued)

B.7. Other Relevant History, Including Preexisting Medical Conditions (e.g., allergies, pregnancy, smoking and alcohol use, hepatic renal dysfunction, etc.) (continued)

F. Concomitant Medical Products and Therapy Dates (Exclude treatment of event) (continued)